5 terminated. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 5 |
Follow Hyperkalemia: new trials by email Literature Review of Hyperkalemia trials Research Report on Hyperkalemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patiromer Trial in CKD Stage IIIB to V Veltassa Oral Powder Product, Placebo - Hyperkalemia | Phase 3 | Terminated | Mario Negri Institute for Pharmacological Research | 2 | 2023-08-02 | 2024-11-12 |
| A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril - Renal Insufficiency, Chronic, Hyperkalemia | Phase 3 | Terminated | AstraZeneca | 1112 | 2021-09-30 | 2026-01-08 |
| Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) Sodium Zirconium Cyclosilicate (SZC), SZC Placebo - Hyperkalemia | Phase 3 | Terminated | AstraZeneca | 2690 | 2021-04-30 | 2025-06-18 |
| Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Sodium zirconium cyclosilicate, Placebo - Hyperkalaemia, Metabolic Acidosis | Phase 3 | Terminated | AstraZeneca | 39 | 2021-03-22 | 2023-10-06 |
| VA NEPHRON-D: Diabetes iN Nephropathy Study losartan, lisinopril - Kidney Disease, Nephropathy | Phase 3 | Terminated | US Department of Veterans Affairs | 1448 | 2008-07-01 | 2015-05-29 |
Renal Insufficiency, Chronic (3) · Acidosis (1) · Acute Kidney Injury (1) · Atrial Fibrillation (1) · Diabetes Mellitus, Type 2 (1) · Kidney Diseases (1) · Tachycardia, Ventricular (1)
Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5) · Water-Electrolyte Imbalance (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Renal Insufficiency (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Chronic Disease (3) · Disease Attributes (3) · Kidney Diseases (3) · Acid-Base Imbalance (1)
sodium zirconium cyclosilicate (3) · Lisinopril (2) · Irbesartan (1) · Losartan (1) · Valsartan (1)
AstraZeneca (3) · Mario Negri Institute for Pharmacological Research (1) · US Department of Veterans Affairs (1)
United States (4) · Italy (3) · Puerto Rico (3) · Argentina (2) · Brazil (2) · Bulgaria (2) · Canada (2) · China (2) · India (2) · Japan (2) · Malaysia (2) · Mexico (2) · Poland (2) · Russia (2) · Spain (2)
Giuseppe Remuzzi, MD (1) · Glenn M. Chertow, MD, MPH (1) · Linda Fried, MD MPH (1) · Steven Fishbane, Professor, MD (1)
PMID 24206457, PMID 24552328, PMID 25014549, PMID 25157242, PMID 30445841, PMID 37230521, PMID 38622759, PMID 38682786, PMID 40548378, PMID 40618849
2023 (1)